免疫检查点抑制剂小肠结肠炎与特发性炎症性肠病的对比
本文综述免疫检查点抑制剂小肠结肠炎(IMEC)与特发性炎症性肠病(克罗恩病、溃疡性结肠炎、显微镜结肠炎)在病理生理、临床表现、评估和管理方面的异同。IMEC是肠道免疫监视破坏和菌群失调导致的炎症性肠病样免疫相关不良事件,两者临床和内镜表现极为相似,常据此指导管理;IMEC的长期结局尚不清楚。
要点
- IMEC是免疫检查点抑制剂最常见的毒性,表现酷似特发性炎症性肠病。
- IMEC由肠道免疫监视破坏和菌群失调所致,与特发性炎症性肠病有重叠。
- 两者临床和内镜表现极为相似,常据此指导管理;IMEC长期结局尚不清楚。
核心结论
- IMEC是一种炎症性肠病样免疫相关不良事件,由肠道免疫监视破坏和菌群失调所致。
- IMEC与特发性炎症性肠病的临床和内镜表现极为相似,常据此指导管理。
- 特发性炎症性肠病的长期结局已明确,但IMEC的长期结局尚不清楚。
研究设计与样本
- 本文为综述,比较免疫检查点抑制剂小肠结肠炎与特发性炎症性肠病(克罗恩病、溃疡性结肠炎、显微镜结肠炎)的病理生理、临床表现、评估和管理。
主要发现
- IMEC是免疫检查点抑制剂最常见的毒性。
- IMEC与特发性炎症性肠病在病理生理、临床表现、评估和管理方面存在异同。
- 两者临床和内镜表现极为相似;IMEC的长期结局尚不清楚。
局限性
- 原文指出IMEC的长期结局尚不清楚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune checkpoint inhibitors have revolutionized management of advanced malignancies. However, their use is frequently complicated by immune related adverse events (irAEs), immune checkpoint inhibitor enterocolitis (IMEC) being the most common toxicity. IMEC is a distinct form of bowel inflammation that is highly reminiscent of idiopathic inflammatory bowel disorders (Crohn's disease, ulcerative colitis, and microscopic colitis). In this review, we highlight the similarities and differences in the pathophysiology, clinical presentation, evaluation, and management of these overlapping immune inflammatory bowel disorders. IMEC is an inflammatory bowel disease-like irAE that occurs as an outcome of disruption of intestinal immune surveillance and gut dysbiosis. Clinical and endoscopic presentation of both entities is strikingly similar, which often guides management. Though well established in inflammatory bowel disease, little is known about the long term outcomes of IMEC.
引用
- Shirwaikar Thomas A, Hanauer S, Wang Y, et al. Immune Checkpoint Inhibitor Enterocolitis vs Idiopathic Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2022. PMID: 36270617. doi:10.1016/j.cgh.2022.10.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。